BrainStorm Cell Therapeutics Inc. Receives 3 Million NIS Grant From Israel’s Office of the Chief Scientist

Published: Dec 12, 2012

NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--BrainStorm Cell Therapeutics Inc. (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Brainstorm Cell Therapeutics Ltd. was awarded a 3 million NIS grant from Israel’s Office of the Chief Scientist (OCS) for the year 2013. The grant is intended to support BrainStorm’s Research and Development program for its innovative stem cell therapy candidate NurOwn.

Back to news